Bank OZK Sells 49 Shares of Amgen Inc. (NASDAQ:AMGN)

Bank OZK lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,801 shares of the medical research company’s stock after selling 49 shares during the quarter. Amgen comprises 1.3% of Bank OZK’s portfolio, making the stock its 20th largest holding. Bank OZK’s holdings in Amgen were worth $3,076,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the third quarter worth approximately $25,000. Centricity Wealth Management LLC acquired a new position in shares of Amgen during the fourth quarter worth approximately $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the third quarter worth approximately $29,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter worth approximately $36,000. Finally, PrairieView Partners LLC lifted its holdings in shares of Amgen by 118.3% during the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after buying an additional 97 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on AMGN shares. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Redburn Partners cut their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler Companies restated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $314.09.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $308.06 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a 50 day moving average of $280.87 and a 200-day moving average of $300.16. The company has a market capitalization of $165.49 billion, a P/E ratio of 40.80, a P/E/G ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.09%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is currently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.